Drug intelligence / Profile preview

Forasartan

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

Forasartan is a pharmaceutical agent that functions as an AT1-receptor antagonist and has been identified as a potential full agonist for Peroxisome Proliferator-Activated Receptor alpha (PPARα). It has been studied for its ability to inhibit angiotensin II-induced increases in heart rate by blocking the AT1 receptor in cardiac sympathetic ganglia. Furthermore, Forasartan has been explored in drug repurposing initiatives as a potential therapeutic candidate for Non-Alcoholic Steatohepatitis (NASH) due to its agonistic activity on PPARα.

Targets

AGTR1 (Angiotensin II Type-1 receptor)PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on Forasartan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forasartan.

Explore the full profile